全文获取类型
收费全文 | 1607篇 |
免费 | 199篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 55篇 |
妇产科学 | 21篇 |
基础医学 | 160篇 |
口腔科学 | 41篇 |
临床医学 | 227篇 |
内科学 | 290篇 |
皮肤病学 | 103篇 |
神经病学 | 43篇 |
特种医学 | 134篇 |
外科学 | 247篇 |
综合类 | 96篇 |
现状与发展 | 30篇 |
预防医学 | 60篇 |
眼科学 | 17篇 |
药学 | 41篇 |
中国医学 | 3篇 |
肿瘤学 | 217篇 |
出版年
2024年 | 14篇 |
2023年 | 180篇 |
2022年 | 14篇 |
2021年 | 23篇 |
2020年 | 59篇 |
2019年 | 22篇 |
2018年 | 52篇 |
2017年 | 47篇 |
2016年 | 41篇 |
2015年 | 57篇 |
2014年 | 88篇 |
2013年 | 69篇 |
2012年 | 43篇 |
2011年 | 54篇 |
2010年 | 87篇 |
2009年 | 98篇 |
2008年 | 53篇 |
2007年 | 86篇 |
2006年 | 41篇 |
2005年 | 46篇 |
2004年 | 41篇 |
2003年 | 31篇 |
2002年 | 30篇 |
2001年 | 28篇 |
2000年 | 31篇 |
1999年 | 42篇 |
1998年 | 39篇 |
1997年 | 53篇 |
1996年 | 47篇 |
1995年 | 41篇 |
1994年 | 29篇 |
1993年 | 37篇 |
1992年 | 9篇 |
1991年 | 9篇 |
1990年 | 10篇 |
1989年 | 22篇 |
1988年 | 20篇 |
1987年 | 14篇 |
1986年 | 4篇 |
1985年 | 11篇 |
1984年 | 4篇 |
1983年 | 6篇 |
1982年 | 9篇 |
1981年 | 10篇 |
1980年 | 13篇 |
1978年 | 5篇 |
1977年 | 7篇 |
1976年 | 16篇 |
1975年 | 14篇 |
1974年 | 7篇 |
排序方式: 共有1824条查询结果,搜索用时 78 毫秒
71.
72.
73.
74.
Classifying CT/MR findings in patients with suspicion of hepatocellular carcinoma: Comparison of liver imaging reporting and data system and criteria‐free Likert scale reporting models
下载免费PDF全文
![点击此处可从《Journal of magnetic resonance imaging : JMRI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
75.
The p53 tumor suppressor is mutated in most human tumors. MDM2, a well-known inhibitor of p53, is overexpressed in a large number of tumors, suggesting that increased levels of MDM2 also contribute to tumorigenesis. A novel p53 inhibitor, MDM4, was more recently identified. The role of MDM4 in cancer development is not well understood. We set out to examine the levels of MDM4 by immunohistochemistry in head and neck squamous carcinomas (HNSC) to ask whether high MDM4 levels could contribute to its development and progression. In addition, MDM2 and p53 levels were examined to identify overlapping expression patterns. MDM4 is present at high levels in 50% of HNSC. In addition, overexpression of MDM2 was detected in 80% of tumors, many of which were also positive for MDM4. A subset of tumors displayed high levels of all 3 proteins. Sequencing of the p53 gene revealed that tumors with positive immunoreactivity for MDM2 or MDM4, some of which also had high levels of p53, did not carry mutations in this gene. Thus, the detection of p53 by immunohistochemistry was not synonymous with the presence of p53 mutations. Expression of both MDM2 and MDM4 in tumors without p53 mutations strongly suggests that MDM2 and MDM4 inhibit the activity of this tumor suppressor in HNSC. 相似文献
76.
A. Touré D. Cissé KJJO. Kadio A. Camara FA. Traoré A. Delamou S. Sididé C. Kouyaté IS. Bangoura MM. Diallo TM. Tounkara F. Traoré MS. Sow N. Khanafer M. Cissé 《Revue d'épidémiologie et de santé publique》2018,66(4):273-279
Background
Late or inadequate therapeutic management increases the risk of mortality associated with HIV/AIDS. The aim of this study was to analyze the proportion and factors associated with loss of follow-up in HIV patients who receiving antiretroviral therapy at Conakry.Methods
A retrospective cohort study was conducted in HIV patients aged over 15 years and who receiving antiretroviral therapy. Between August 1, 2008 and July 31, 2015, all patients managed by the ambulatory treatment center of the Guinean Women Association against AIDS and sexually and transmissible infection were included. Loss of follow-up was defined as no follow-up visit within 3 months. Kaplan–Meier curves and multivariate Cox regression modelResults
614 patients aged 36.3 ± 11.2 years, mainly females (68.4%) and living in Conakry (80.5%) were included. Among them, 104 were loss to follow-up, corresponding to a proportion rate of 16.9% (95% CI: 14.2–19.7%) or 5.79/100 person-years. The results of multivariate analyses showed that factors independently associated with loss of follow-up were malnutrition (AHR = 7.05; 95% CI: 2.05–24.27; P = 0.002) and CD4 cells account at the initiation of AHR (2.35; 95% CI: 1.61–6.39; P = 0.016) in patients with 201–350 CD4/μL and 5.83 (95% CI: 2.85–11.90; P < 0.001) in patients with less than 150 CD4/μL.Conclusion
Despite efforts of health care workers and free antiretroviral therapy, many patients were loss to follow-up. Multivariate analysis showed that malnutrition and low CD4 account were independently associated with loss to follow-up. 相似文献77.
78.
79.
F. Wang MClinEpid FRACS A. J. Gill MD FRACP M. Neale MM FRACS V. Puttaswamy MBBS FRACS S. Gananadha MS FRACS N. Pavlakis PhD FRACP S. Clarke MD FRACP T. J. Hugh MD FRACS J. S. Samra DPhil FRACS 《Annals of surgical oncology》2014,21(6):1937-1947
Background
Although pancreatoduodenectomy (PD) with mesenterico-portal vein resection (VR) can be performed safely in patients with resectable pancreatic ductal adenocarcinoma (PDAC), the impact of this approach on long-term survival is controversial.Patients and Methods
Analyses of a prospectively collected database revealed 122 consecutive patients with PDAC who underwent PD with (PD+VR) or without (PD?VR) VR between January 2004 and May 2012. Clinical data, operative results, and survival outcomes were analysed.Results
Sixty-four (53 %) patients underwent PD+VR. The majority (84 %) of the venous reconstructions were performed with a primary end-to-end anastomosis. Demographic and postoperative outcomes were similar between the two groups. American Society of Anesthesiologists (ASA) score, duration of operation, intraoperative blood loss, and blood transfusion requirement were significantly greater in the PD+VR group compared with the PD?VR group. Furthermore, the tumor size was larger, and the rates of periuncinate neural invasion and positive resection margin were higher in the PD+VR group compared with the PD?VR group. Histological venous involvement occurred in 47 of 62 (76 %) patients in the PD+VR group. At a median follow-up of 29 months, the median overall survival (OS) was 18 months for the PD+VR group, and 31 months for the PD?VR group (p = 0.016). ASA score, lymph node metastasis, neurovascular invasion, and tumor differentiation were predictive of survival. The need for VR in itself was not prognostic of survival.Conclusions
PD with VR has similar morbidity but worse OS compared with a PD?VR. Although VR is not predictive of survival, tumors requiring a PD+VR have more adverse biological features. 相似文献80.